Letter to the Editor concerning “ Single-institution experience of performing bloodless transplant in Jehovah’s Witness patients” by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol Oncol Stem Cell Ther 2019;12(1):44–9.)

Publication date: Available online 11 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jennifer C. Zhao, Justin R. Arnall, Allison L. Martin, Saad Usmani, Shebli Atrash
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 14 November 2019Source: Stem Cell ReportsAuthor(s): Natacha A. Agabalyan, Holly D. Sparks, Samar Tarraf, Nicole L. Rosin, Katie Anker, Grace Yoon, Lindsay N. Burnett, Duncan Nickerson, Elena S. Di Martino, Vincent A. Gabriel, Jeff BiernaskieSummaryFollowing full-thickness skin injuries, epithelialization of the wound is essential. The standard of care to achieve this wound “closure” in patients is autologous split-thickness skin grafting (STSG). However, patients living with STSGs report significant chronic impairments leading to functional deficiencies such as itch, altered s...
Source: Stem Cell Reports - Category: Stem Cells Source Type: research
Abstract Pulmonary arterial hypertension (PAH) is a serious condition. However, prevailing therapeutic strategies are not effective enough to treat PAH. Therefore, finding an effective therapy is clearly warranted. Adipose-derived mesenchymal stem cells (ASCs) and ASCs-derived exosomes (ASCs-Exos) exert protective effects in PAH, but the underlying mechanism remains unclear. Using a coculture of ASCs and monocrotaline pyrrole (MCTP)-treated human pulmonary artery endothelial cells (HPAECs), we demonstrated that ASCs increased cell proliferation in MCTP-treated HPAECs. Results showed that ASCs-Exos improved prolife...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
CONCLUSION: Both HZ and PHN are associated with considerable disutility in recipients of auto-HSCT. Costs were comparable to published estimates in other immunocompromised subjects.The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT01229267). PMID: 31721601 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
We describe two cases of GVHD with clinical and histopathologic features of pityriasis rubra pilaris (PRP), which responded to additional immunosuppression. Recognition of this newly described PRP‐like clinical presentation of GVHD may pro mpt early consideration of additional steroid‐sparing therapies. AbstractChronic cutaneous graft ‐vs‐host disease (GVHD) has several atypical variants. We describe two cases of GVHD with clinical and histopathologic features of pityriasis rubra pilaris (PRP), which responded to additional immunosuppression. Recognition of this newly described PRP‐like clinical presentation of G...
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
Conclusions: The current report includes the first in-depth study of allo-incompatability and antigenic specificity in anti-GBM disease occurring after allogeneic haematopoietic stem cell transplant (HSCT). No polymorphic genetic differences were identified between donor and recipient collagen IV genes which would be predicted to provide a target for antibody binding. Furthermore, autoantibody binding to native α345NC1 hexamer was minimal, increasing greatly upon dissociation of the native hexamer, resembling wild-type GP diseases and marking this as the first example of a post-HSCT conformeropathy.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
SummaryChimeric antigen receptor (CAR) T  cells are genetically engineered cells containing fusion proteins combining an extracellular epitope-specific binding domain, a transmembrane and signaling domains of the T cell receptor. The CD19-CAR T cell product tisagenlecleucel has been approved by the US Food and Drug Administration and t he European Medicines Agency for therapy of children and young adults under 25 years with relapsed/refractory B‑cell acute lymphoblastic leukemia (ALL) due to a high overall response rate of 81% at 3 months after therapy. The rates of event-free and overa...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
AbstractHaematopoietic stem cells (HSCs) are the only adult stem cells with a demonstrated clinical use, even though a tractable method to maintain and expand human HSCsin vitro has not yet been found. Owing to the introduction of transplantation strategies for the treatment of haematological malignancies and, more recently, the promise of gene therapy, the need to improve the generation, manipulation, and scalability of autologous or allogeneic HSCs has risen steeply over the past decade. In that context, reprogramming strategies based on the expression of exogenous transcription factors have emerged as a means to produce...
Source: FEBS Letters - Category: Biochemistry Authors: Tags: Review Source Type: research
Cord blood (CB) represents an alternative source of stem cells for hematopoietic stem cell transplantation (HSCT) [1]. Hematopoietic stem cells (HSC) express high number of the cell surface glycoprotein CD34+ which is associated with stem cell engraftment [1]. MPs represent a part of the extracellular vesicles with various size (100-1000nm) and content [2], released from cells during apoptosis or activation [3]. MPs are produced by budding from the plasma membrane after rearrangement of cytoskeleton which leads to the exposure of phosphatidylserine (PS) [4].
Source: Experimental Hematology - Category: Hematology Authors: Tags: Brief Communication Source Type: research
ConclusionsThese data demonstrate that a transplantation protocol involving only selective tumor-reactive donor T cell families is an effective immunotherapy and results in long-term survival in a mouse model of human MM. The results highlight the need to develop similar ATCT strategies for MM patients that result in enhanced survival without symptoms of GvHD.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Malignant Neoplasm Intervention:   Procedure: Biospecimen Collection Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Hematology | Stem Cell Therapy | Stem Cells | Transplants